{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=blood+biomarker&page=4", "query": { "intervention": "blood biomarker", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 1739, "total_pages": 174, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=blood+biomarker&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=blood+biomarker&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T17:45:40.120Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03178695", "title": "Inovium Ovarian Rejuvenation Trials", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Perimenopausal Disorder", "Menopause", "Menopause, Premature", "Menopause Related Conditions", "Menopause Premature Symptomatic", "Menopause Premature Asymptomatic", "Premature Ovarian Failure", "Premature Ovarian Failure, Familial", "Premature Ovarian Failure 2A", "Premature Ovarian Failure 3", "Premature Ovarian Failure 4", "Premature Ovarian Failure 1", "Premature Ovarian Failure 5", "Premature Ovarian Failure 6", "Premature Ovarian Failure 7", "Premature Ovarian Failure 9", "Premature Ovarian Failure 8", "Infertility", "Infertility, Female", "Infertility Unexplained" ], "interventions": [ { "name": "Autologous PRP injection into human ovarian tissue", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Ascendance Biomedical", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "FEMALE", "summary": "35 Years and older · Female only" }, "enrollment_count": 200, "start_date": "2017-06-01", "completion_date": "2018-05-01", "has_results": false, "last_update_posted_date": "2020-04-20", "last_synced_at": "2026-10-14T17:45:40.120Z", "location_count": 1, "location_summary": "Carlsbad, California", "locations": [ { "city": "Carlsbad", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03178695" }, { "nct_id": "NCT02541565", "title": "Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Composite Lymphoma", "Grade 3b Follicular Lymphoma", "Stage I Diffuse Large B-Cell Lymphoma", "Stage I Follicular Lymphoma", "Stage II Diffuse Large B-Cell Lymphoma", "Stage II Follicular Lymphoma", "Stage III Diffuse Large B-Cell Lymphoma", "Stage III Follicular Lymphoma", "Stage IV Diffuse Large B-Cell Lymphoma", "Stage IV Follicular Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2015-11-24", "completion_date": "2018-12-18", "has_results": true, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-10-14T17:45:40.120Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02541565" }, { "nct_id": "NCT02879695", "title": "Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Mixed Phenotype Acute Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Mixed Phenotype Acute Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 28, "start_date": "2017-10-25", "completion_date": "2027-07-18", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-14T17:45:40.120Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Lexington, Kentucky • Baltimore, Maryland + 4 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02879695" }, { "nct_id": "NCT02051257", "title": "Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Mantle Cell Lymphoma", "Transformed Recurrent Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells", "type": "BIOLOGICAL" }, { "name": "Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2014-06-19", "completion_date": "2027-03-02", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-10-14T17:45:40.120Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02051257" }, { "nct_id": "NCT00114101", "title": "Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "DS Stage I Multiple Myeloma", "DS Stage II Multiple Myeloma", "DS Stage III Multiple Myeloma", "Refractory Multiple Myeloma", "Smoldering Multiple Myeloma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Placebo Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 460, "start_date": "2004-12-15", "completion_date": "2027-03-06", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-14T17:45:40.120Z", "location_count": 140, "location_summary": "Scottsdale, Arizona • Duarte, California • Sacramento, California + 103 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00114101" }, { "nct_id": "NCT03263429", "title": "Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Metastatic Colorectal Cancer", "RAS Wild Type Colorectal Cancer", "Refractory Colorectal Cancer" ], "interventions": [ { "name": "Glutaminase Inhibitor CB-839", "type": "DRUG" }, { "name": "Panitumumab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride (phase I only)", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "DEVICE" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2017-08-23", "completion_date": "2023-12-21", "has_results": true, "last_update_posted_date": "2024-08-30", "last_synced_at": "2026-10-14T17:45:40.120Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03263429" }, { "nct_id": "NCT03563651", "title": "Collection of Blood, Urine, and Stool to Monitor MetastaticColorectal Cancers", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stage III Colorectal Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2014-02-06", "completion_date": "2020-05-28", "has_results": false, "last_update_posted_date": "2021-11-18", "last_synced_at": "2026-10-14T17:45:40.120Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563651" }, { "nct_id": "NCT03628651", "title": "Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatocellular Carcinoma", "Hepatocellular Carcinoma Surveillance" ], "interventions": [ { "name": "Blood Sample Collection", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Exact Sciences Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2150, "start_date": "2018-04-02", "completion_date": "2020-03-11", "has_results": false, "last_update_posted_date": "2020-08-06", "last_synced_at": "2026-10-14T17:45:40.120Z", "location_count": 36, "location_summary": "Los Angeles, California • Newport Beach, California • Orange, California + 29 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Oxnard", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03628651" }, { "nct_id": "NCT00050102", "title": "Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "MDX-010 (CTLA-4)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2002-10", "completion_date": "2004-02", "has_results": false, "last_update_posted_date": "2011-01-28", "last_synced_at": "2026-10-14T17:45:40.120Z", "location_count": 9, "location_summary": "Tucson, Arizona • Long Beach, California • Los Angeles, California + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00050102" }, { "nct_id": "NCT02781272", "title": "Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "Pelvic imaging", "type": "PROCEDURE" }, { "name": "Blood draw", "type": "PROCEDURE" }, { "name": "Imaging guided biopsy, surgical biopsy or surgical excision", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Angle plc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 200, "start_date": "2016-06-30", "completion_date": "2022-06-27", "has_results": false, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-10-14T17:45:40.120Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02781272" } ] }